ADMA Biologics Inc (ADMA)vsNovartis AG ADR (NVS)
ADMA
ADMA Biologics Inc
$8.75
+0.34%
HEALTHCARE · Cap: $2.02B
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 10997% more annual revenue ($56.58B vs $509.86M). ADMA leads profitability with a 32.4% profit margin vs 23.9%. ADMA trades at a lower P/E of 12.8x. NVS earns a higher WallStSmart Score of 49/100 (D+).
ADMA
Hold49
out of 100
Grade: D+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 32 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
15.9% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Earnings declined 52.8%
Operating margin of -123.4%
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Altman Z-Score. Profitability is solid with margins at 32.4% and operating margin at -123.4%. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth, Operating Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
ADMA profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
ADMA carries more volatility with a beta of 0.73 — expect wider price swings.
ADMA is growing revenue faster at 15.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ADMA scores higher overall (49/100 vs 49/100), backed by strong 32.4% margins and 15.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?